DermTech, Inc.

DermTech, Inc. (Nasdaq: DMTK) is a precision dermatology company that entered the public markets through a business combination with Constellation Alpha Capital Corp, a healthcare-focused special purpose acquisition company sponsored by Constellation Alpha Capital LLC that completed its IPO in 2017. The company operates in the medical diagnostics sector, developing non-invasive genomic skin analysis tools designed to improve early detection of conditions such as melanoma. DermTech filed an S-1 registration statement with the SEC on May 4, 2020, in connection with its post-merger public reporting obligations as a Nasdaq-listed entity. For comprehensive filing history, sponsor profiles, and deal analytics on DermTech and thousands of other SPAC transactions, sign up for full data access at SpacDesk.